Harbin Pharmaceutical shares to cash share reform Commitment group additional price per share 24.11 yuan

Harbin Pharmaceutical shares (600664. SH) announced today announcing the issuance of shares to purchase assets and related trading plans. This major asset restructuring program is: Harbin Pharmaceutical shares to Harbin Pharmaceutical group Non-public offering shares, the acquisition of Harbin Pharmaceutical Group Holdings of bio-engineering companies and the target assets of the three sperm pharmaceutical.　　After the completion of the acquisition, Harbin Pharmaceutical shares will hold 100% per cent of bioengineering companies, three refining drugs will rise from 30% to 74.82%, Harbin Pharmaceutical group no longer hold the shares of three refined drugs. On December 31, 2010 as the benchmark day, the initial estimate of the assets of the bioengineering company is 1.85 billion yuan.　　The proposed purchase of assets of the estimated transaction price of 5.747 billion yuan, the company to the Harbin Pharmaceutical Group issued a shares of Non-public offering price of 24.11 yuan/share. East China Sea Securities and pharmaceutical analyst Bos that the injected assets, the group's holdings of the three outstanding pharmaceutical remaining 44.8% equity, as well as the production of veterinary drugs, animal vaccines, bio-vaccine companies and production of interferon and EPO gene products of bioengineering companies, excellent asset quality, in their respective areas have a strong competitive advantage,　　Will significantly enhance the company's performance and value. The expected transaction price of the proposed assets is 5.747 billion yuan, the total assets of the company as at December 31, 2009 amounted to 10.007 billion yuan, the proposed assets are expected to buy the transaction price of the company up to December 31, 2009 the proportion of the total assets of 57.43%.　　In accordance with the provisions of articles 11th and 12th of the regulations on the management of major assets reorganization, this transaction constitutes a significant reorganization of assets and, as a result of the purchase of assets involving Non-public offerings, it is still subject to review by the China Securities Regulatory Commission merger and reorganization Audit Committee. The pricing base date of this issue shares is the day of the 24th meeting of the fifth session of the Board of Directors to consider the issue of shares purchase assets and related transaction plans to Harbin Pharmaceutical group. The price per share of the non-public offering of the Harbin Pharmaceutical group is not less than the average of 20 trading days of the company's stock. By agreement, the company to Harbin Pharmaceutical Group Non-public issue A shares of the issue price of 24.11 yuan/share.　　If the company has dividend, Shang, capital accumulation to increase equity, etc., the pricing base date to the issue date, the above issue price will be adjusted accordingly.　　According to the company, the above estimate is only a preliminary evaluation result, because of the uncertainty of the domestic macro-economic operation, the final transaction price may have some difference with the above estimate. The acquisition of bio-engineering companies in 2008, 2009, 2010 net profit of 9.6284 million yuan, 28.7198 million yuan, 100.1621 million yuan (unaudited), profit growth faster; three refining drugs 2008 years, 2009 and 2010 three quarterly net profit steady growth, 280.6797 million yuan, 293.5205 million yuan, 261.7826 million yuan respectively. Although the three sperm industry in recent years to maintain a good profit posture, but the future will be able to maintain the continued profitability of aFixed uncertainty. 2008 Harbin Pharmaceutical shares completed the share reform, commitment in the 30 months after the reform (February 2011), Harbin Pharmaceutical Group in private distribution or other ways to inject assets and cash assets not less than 2.611 billion yuan, and within 36 months of implementation (before August 2011). Harbin Pharmaceutical shares since the suspension of December 29 last year, the first trading day before the closing, closed slightly down 1.35%, the report received 22.57 yuan.